Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024 – By Drug Class (Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 175 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Vasomotor Menopausal Symptoms VMS Treatment Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN

Vasomotor Menopausal Symptoms (VMS) Treatment Market Definition And Segments

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain.

The main types of drugs in vasomotor menopausal symptoms (VMS) treatment are antidepressants, fluoxetine, paroxetine, sertraline, hormone therapy, anticonvulsants, phenytoin, phenobarbital and others. Antidepressants refer to a class of medications primarily used to treat depression and certain other mental health disorders. They are distributed in several ways, such as in hospital pharmacies, online pharmacies, retail pharmacies and others for various end-users such as hospitals, specialty clinics, homecare and others.

The vasomotor menopausal symptoms (vms) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

The vasomotor menopausal symptoms (vms) treatment market size has grown strongly in recent years. It will grow from $16.6 billion in 2023 to $17.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.

The vasomotor menopausal symptoms (vms) treatment market size is expected to see strong growth in the next few years. It will grow to $23.11 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).

Menopausal Population Growth Fuels Expansion Of Vasomotor Menopausal Symptoms Treatment Market

The increase in the menopause population is expected to propel the growth of the vasomotor menopausal symptoms treatment market going forward. Menopause is a natural biological process that marks the end of a woman's reproductive years. It is a significant life stage that typically occurs in women between the ages of 45 and 55, with the average age being around 51. The rising number of menopausal women, which demands treatment for hot flashes and vaginal dryness globally, is one of the primary factors pushing the growth of vasomotor menopausal symptoms (VMS) treatment. For instance, in November 2022, according to the Cuyuna Regional Medical Center, a US-based organization, estimated that by 2025, 1.1 billion women will be menopausal due to women living longer. Moreover, the population of menopausal will be increased by 1.6% annually until 2060. Therefore, the increase in the menopause population is driving the growth of the vasomotor menopausal symptoms treatment market.

Government Women's Health Initiatives Boost Vasomotor Menopausal Symptom Treatment Market

The government's initiatives for women's health in menopause are expected to propel the growth of the vasomotor menopausal symptom’s treatment market going forward. Government initiatives for menopausal health encompass funding for innovative studies on menopausal transition, illness prevention, and research related pharmacological, clinical, and epidemiological aspects. These efforts are part of broader women's health initiatives that address diverse concerns. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government initiated $40.3 million over four years (2022-2023 to 2025-2026) to build up to 16 new programs for women facing severe menopausal symptoms. Therefore, the government's initiatives for women's health in menopause are driving the growth of the vasomotor menopausal symptoms’ treatment market.

Major players in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

Adverse Effects Of Hormone Therapy Impact The Vasomotor Menopausal Symptoms (VMS) Treatment Market

Adverse effects of hormone therapy pose a challenge and may limit the market's expansion during the forecast period. Women who are aware of the adverse effects of hormone therapy may be less likely to seek treatment for vasomotor menopausal symptoms (VMS), which could reduce patient demand for hormone therapy. For instance, in March 2023, the National Institutes of Health (NIH), a US federal agency, reported that following the hormone therapy, 89.7% of Group M (most commonly stated side effect was mood swings) and 96.3% of Group F (most frequently reported side effect was lower libido) experienced side effects. Therefore, the adverse effects of hormone therapy are hindering the growth of the vasomotor menopausal symptoms (VMS) treatment market.

Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options

Major companies operating in the vasomotor menopausal symptoms treatment market are developing products such as Veozah and getting approvals to provide new treatment options and meet unmet medical needs for patients. The approval of new drugs for menopause provides improved efficacy and safety compared to existing treatments. For instance, in May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval for Veozah (fezolinetant) 45 mg once daily from the Food and Drug Administration (FDA), a US-based federal agency for the treatment of menopausal vasomotor symptoms (VMS), which range from mild to severe. It is the first nonhormonal neurokinin 3 (NK3) receptor antagonist to be authorized for treating menopausal-related VMS. It is a hormone-free option that blocks a pathway in the brain that helps regulate these symptoms. It provides an alternative treatment option for women experiencing these symptoms, particularly those who cannot or prefer not to use hormone therapy. The approval of Veozah highlights its potential as a new drug for managing menopausal symptoms.

Amyris Inc. Expands Women's Health Portfolio With Acquisition Of Menolabs Llc

In March 2022, Amyris Inc., a US-based biotechnology company, acquired MenoLabs LLC for $35.4 million. With this acquisition, Amyris aims to expand its women's health market presence, gain access to new technologies and capabilities and acquire a loyal customer base. MenoLabs LLC is a US-based women's health and technology company that develops dietary supplements to treat women's menopause symptoms.

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2023. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The vasomotor menopausal symptoms (VMS) treatment market research report is one of a series of new reports from The Business Research Company that provides vasomotor menopausal symptoms (VMS) treatment market statistics, including vasomotor menopausal symptoms (VMS) treatment industry global market size, regional shares, competitors with a vasomotor menopausal symptoms (VMS) treatment market share, detailed vasomotor menopausal symptoms (VMS) treatment market segments, market trends and opportunities and any further data you may need to thrive in the vasomotor menopausal symptoms (VMS) treatment industry. This vasomotor menopausal symptoms (VMS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

    Table Of Contents

    1. Executive Summary

    2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics

    3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies

    4. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Size and Growth

    5.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

    6.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Antidepressants

    Fluoxetine

    Paroxetine

    Sertraline

    Hormone Therapy

    Anticonvulsant

    Phenytoin

    Phenobarbital

    Other Drug Classes

    6.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    Other Distribution Channels

    6.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Specialty Clinics

    Homecare

    Other End-Users

    7. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional And Country Analysis

    7.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    8.1. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    9.1. China Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview  

    9.2. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    10.1. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    11.1. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview  

    11.2. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    12.1. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    13.1. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    14.1. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview  

    14.2. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    15.1. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

    15.2. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    16.1. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    17.1. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    18.5. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    19.9. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    20.13. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    21.1. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

    21.2. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    22.1. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    23.1. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

    23.2. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    24.1. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

    24.2. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    25.1. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

    25.2. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    26.1. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

    26.2. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    27.1. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    28.1. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

    28.2. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market  

    29.1. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

    29.2. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles

    30.1. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape

    30.2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Abbvie Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Novartis AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Ausio Pharmaceuticals LLC

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Teva Pharmaceutical Industries Ltd.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Vasomotor Menopausal Symptoms (VMS) Treatment Market Other Major And Innovative Companies

    31.1. Mylan N.V.

    31.2. Sun Pharmaceutical Industries Ltd.

    31.3. Aurobindo Pharma Limited

    31.4. Kyowa Kirin Co. Ltd.

    31.5. Dr. Reddy's Laboratories Ltd.

    31.6. Alembic Pharmaceuticals Limited Inc.

    31.7. Apotex Inc.

    31.8. Hikma Pharmaceutical plc

    31.9. Endo Pharmaceuticals plc

    31.10. Amneal Pharmaceuticals LLC

    31.11. Mundipharma International Ltd.

    31.12. Lupin Limited

    31.13. Glenmark Pharmaceuticals Ltd.

    31.14. Hisamitsu Pharmaceutical Co. Inc.

    31.15. Zhejiang Huahai Pharmaceutical Co. Ltd.

    32. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking

    33. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

    35. Vasomotor Menopausal Symptoms (VMS) Treatment Market Future Outlook and Potential Analysis

    35.1 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2028 - Countries Offering Most New Opportunities

    35.2 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2028 - Segments Offering Most New Opportunities

    35.3 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Pfizer Inc. Financial Performance
  • Table 75: Abbvie Inc. Financial Performance
  • Table 76: Novartis AG Financial Performance
  • Table 77: Ausio Pharmaceuticals LLC Financial Performance
  • Table 78: Teva Pharmaceutical Industries Ltd. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Pfizer Inc. Financial Performance
  • Figure 75: Abbvie Inc. Financial Performance
  • Figure 76: Novartis AG Financial Performance
  • Figure 77: Ausio Pharmaceuticals LLC Financial Performance
  • Figure 78: Teva Pharmaceutical Industries Ltd. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report